

March 5, 2024

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

To all stakeholders,

**Adoption as Tokyo Strategic Innovation Promotion Program**  
**by Tokyo Metropolitan Small and Medium Enterprise Support Center**

Perseus Proteomics Inc. ("the Company") is pleased to announce that its development of the platform technology to obtain new functional antibodies has been adopted as Tokyo Strategic Innovation Promotion Program.

1. Outline of the adopted development

The Company introduced single B cell cloning technology in 2023 to obtain high-quality functional antibodies quickly and efficiently. Following this adoption, the Company will further refine the technology in cooperation with On-chip Biotechnologies Co., Ltd.\* for increase in sales and profits in its antibody research service and antibody/reagent sales businesses. As the single B cell cloning technology enables obtaining antibodies from patients' blood efficiently, the Company expects to contribute to "Strategy 0. Strategy for Overcoming Infectious Diseases" of Tokyo Metropolitan Government as one of its measures to prevent new infectious diseases.

2. Outline of Tokyo Strategic Innovation Promotion Program

This is a subsidy program to support development of innovative technology/products by small and medium enterprises in Tokyo based on their core technologies, utilizing external knowledge and knowhow, based on the "Innovation Map" formulated by the Tokyo Metropolitan Government.

3. Details of support

Business period: January 1, 2024 to March 31, 2026 (2 fiscal years)

Planned subsidy amount: 80 million yen (maximum)

4. Future forecast

There is no impact on the business results of the fiscal year ending 2024/03. The Company will study the impact on the business results of the fiscal year ending 2025/03 and after.

[Homepage of Tokyo Metropolitan Small and Medium Enterprise Support Center](#)

\*About On-chip Biotechnologies, Co., Ltd. ("On-chip Biotechnologies")

On-chip Biotechnologies develops, manufactures, and sells analytical equipment for life science utilizing microfluid technology. In this development, the Company develops the method to obtain high-quality



functional antibodies efficiently utilizing the single cell analytical technology of cells/microorganisms employing water-in-oil by On-chip Biotechnologies. HQ: Koganei-shi, Tokyo.

END